Inflammatory Disease Clinical Trial
— DIRECTCDOfficial title:
A Multicenter Randomized, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy With Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn's Disease
Study Design: A Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous (SC) Infliximab (IFX) with and without Immunomodulators during Induction treatment in Moderate to Severe Crohn's Disease. Primary endpoint: The proportion of patients in corticosteroid-free clinical remission (as defined by a Crohn's disease activity index (CDAI)<150) and endoscopic response (as defined by a simple endoscopic score for Crohn's disease (SES-CD) drop of at least 50%) at week 26. Accrual and feasibility: This study will enroll 158 subjects at approximately 20 sites in the Netherlands (peripheral and academic hospitals). The estimated enrollment is 0.5 patient/centre/month leading to an inclusion duration of 16 months once all centres are open. The first enrolment is anticipated in Q1 2021. Treatment, dosage and administration: Eligible patients will be randomized to receive SC IFX monotherapy (240mg at week 0 and week 2 and then 120mg every other week (EOW) OR SC IFX (240mg at week 0 and week 2 and then 120mg EOW) in combination with immunosuppression.
Status | Recruiting |
Enrollment | 158 |
Est. completion date | July 2024 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patients 18 years or older diagnosed with Crohn's disease 2. Patients with moderate to severely active Crohn's disease with a Crohn's Disease Activity Index (CDAI) of 250 to 450 and presence of endoscopic ulceration in the terminal ileum, colon or both. Minimal SES-CD is = 6 or = 4 for isolated ileal disease. 3. Patients who had no response or loss of response to or have had intolerable side effects to one or more to the following: glucocorticoids, thiopurines (azathioprine/6-mercaptopurine/6-thioguanin), methotrexate , adalimumab, vedolizumab or ustekinumab OR patients in need of immediate top-down treatment with IFX at the discretion of the treating physician. 4. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements. 5. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedure. 6. Male or non-pregnant, non-lactating females. No wish to become pregnant in the coming 26 weeks. Exclusion Criteria: 1. Patients at imminent need of surgery as judged by the treating clinician 2. Patients with the short bowel syndrome, an ostomy or a symptomatic non-inflammatory stricture 3. Patients previously exposed to IFX (intravenous or subcutaneous) 4. Previously unacceptable side effects or intolerance to all immunosuppressants (both thiopurines and methotrexate) 5. Treatment with adalimumab or vedolizumab or ustekinumab within 30 days 6. Patients who have had a primary non-response to adalimumab or had intolerable class-related side effects (as evaluated at the discretion of the treating physician) 7. Enteric pathogens (such as Salmonella, Shigella, Yersinia, Campylobacter and C. difficile) detected by stool analysis within 2 weeks prior to enrollment or at screening 8. Ongoing participation in another interventional trial 9. Patients with Ulcerative Colitis or Inflammatory bowel disease unclassified (IBD-U) 10. Patients with ongoing abdominal or undrained perianal abscess 11. Patients with a history of colon cancer or colonic dysplasia, unless sporadic adenoma, which has been removed 12. Active or latent tuberculosis (screening according to national guidelines). Except when the latter has been treated appropriately according to national guidelines. 13. Cardiac failure in the New York heart Association (NYHA) stage III-IV 14. History of demyelinating disease 15. Recent live vaccination (= 4 weeks) 16. Patients with ongoing acute/chronic infection (including but not limited to HIV, hepatitis B and C) with the exception of chronic herpes labialis or cervical human papillomavirus (HPV) 17. History of cancer in the last 5 years with the exception of non-melanoma skin cancer 18. Male patients with Epstein-Barr virus (EBV) negative serology 19. A history of alcohol or illicit drug use that in the opinion of the principal investigator (PI) would interfere with study procedures 20. Patients with psychiatric problems that in the opinion of the PI would interfere with study procedures 21. Patients unable to attend all study visits 22. Patients with a history of non-compliance with clinical study protocols 23. Contraindication for endoscopy 24. Patients who received any investigational drug in the past 30 days or 5 half-lives, whichever is longer 25. Pregnancy or lactation or wish to become pregnant in the coming 26 weeks |
Country | Name | City | State |
---|---|---|---|
Netherlands | Amsterdam UMC AMC | Amsterdam | North Holland |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Celltrion |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Crohn's disease activity index <150 (-10 to 480) AND endoscopic response , where the higher score means worse outcome . | The proportion of patients in corticosteroid-free clinical remission. | at week 0 and 26 | |
Secondary | Endoscopic remission | The proportion of patients with absence ulcerations larger then 5mm | week 0 and 26 | |
Secondary | Simple Endoscopic score for Crohn's disease =2 ( 0-60) where a higher score means worse outcome | Proportion of patients with endoscopic remission | week 0 and 26 | |
Secondary | Crohn's disease activity index <150 (-10 to 480) where a higher score is a worse outcome | Number of patients in clinical remission | week 0, 2, 4, 8, 14 and 26 | |
Secondary | Crohn's disease activity index improved with 70 points (-10 to 480) where a higher score is a worse outcome. | Proportion of patients achieving clinical response | week 0, 2, 4, 8, 14 and 26 | |
Secondary | Crohn's disease activity index improved by100 points( -10 to 480) where a higher score is a worse outcome | Proportion of patients achieving clinical response | at week 26 | |
Secondary | Patient reported outcome PRO-2 (stool frequency and abdominal pain) <8 (0 to na) where the higher score is the worse outcome | Proportion of patients in symptomatic remission | week 0, 2, 4, 8, 14 and 26 | |
Secondary | CRP = 5.0 mg/L | Proportion of patients in biochemical remission | at week 0 and 4, 8, 14 and week 26 | |
Secondary | Inflammatory bowel disease questionnaire | Proportion of patients achieving minimally clinically important difference in quality of life | at week 0, 2, 4, 8, 14 and week 26 | |
Secondary | Drug-tolerant assay | Proportion of patients developing anti-drug antibodies (ADA) against IFX | week 2, 4, 8, 14 and 26 | |
Secondary | Thiopurine metabolites test | Level of Metabolites 6mmp, 6-tgn | At baseline, week 14 and week 26 (for patients randomized for the combination therapy group. Only at baseline for those in the monotherapy group and with previous IS use) | |
Secondary | IFX concentrate levels | IFX trough levels of > 5ug/ml at week 26 | week 2, 4, 8, 14 and 26 | |
Secondary | Histological analysis | Proportion of patients achieving histological healing | week 0 and week 26 | |
Secondary | Fistula drainage assessment | Proportion of patients (of those with active perianal disease at baseline) in clinical remission and response of their perianal | week 0 and week 26 | |
Secondary | Number of adverse event reports | Number of adverse event recorded in mono and combination therapy group | week 0 to week 26 | |
Secondary | EuroQol-5Dimension-5Level questionnaire | Proportion of patients achieving minimally clinically important difference in quality of life | at week 0, 2, 4, 8, 14 and week 26 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03964324 -
NO Measurements in Screening for Asthma and OSA, in Patients With Severe Snoring
|
N/A | |
Recruiting |
NCT03963648 -
NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP
|
N/A | |
Not yet recruiting |
NCT04997343 -
Neurophysiological Assessment in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT01695876 -
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT05546788 -
Hydroxylated Polymethoxy Flavones Solid Dispersion in Treatment of Periodontitis
|
Phase 1 | |
Recruiting |
NCT03651518 -
Personalized Therapies in Inflammatory Complex Disease
|
Phase 2 | |
Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
Completed |
NCT02552004 -
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study
|
N/A | |
Completed |
NCT04368494 -
Exercise Therapy in Patients With Axial Spondyloarthritis
|
N/A | |
Completed |
NCT03878134 -
Translational Development of Photon-counting CT Imaging
|
N/A | |
Completed |
NCT02959138 -
Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
|
Phase 1 | |
Active, not recruiting |
NCT04565821 -
Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe
|
N/A | |
Recruiting |
NCT05509075 -
Nutraceuticals and Functional Foods
|
||
Active, not recruiting |
NCT06448052 -
Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05944822 -
Pro-inflammatory Cytokines in Case of Essure®
|
||
Completed |
NCT05115370 -
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
|
||
Active, not recruiting |
NCT03604406 -
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
|
Phase 2 | |
Completed |
NCT05022017 -
Description of Statics by EOS Imaging and Evaluation of the Efficacy of Intradiscal Corticosteroid Infiltration
|
||
Recruiting |
NCT05364294 -
Molecular Diagnosis of Systemic Autoinflammatory Diseases
|
||
Recruiting |
NCT05860400 -
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
|